Pfizer Inc PFE

$28.83 -0.62 (-2.11%)

Valuation

Market cap
167,860,704,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.63
P/E (forward)
9.65
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
30,780,121
Avg volume
33,193,344
Day's range
$28.83 – $29.77
Shares out
5,699,854,000
Stochastic %K
10%
Beta
0.31
Analysts
Hold
Price target
$30.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

TraderDaKing Nov 13, 5:10 PM
$ELTP $PFE $JNJ $MRNA Make Room for ELTP.... We are in. this is Huge News. If you did not hear the call, you must replay and listen. We are going to the Moon. This is the Cheapest the stock will ever be. Thank You.
0 replies
markarchibald Nov 13, 4:48 PM
$PFE StO 2x 11/20 30/CC for.08
0 replies
SellasgpsCurativeBAT11 Nov 13, 4:38 PM
$ABBV $BMY $JNJ $PFE $SLS Data is a Overwhelming success is a forgone conclusion for me. As a Biostatistician Sellas GPS has blown past all my Analysis. I am here for the Big Pharmaceutical BO. Sellas has structured itself so lean for an immediate BO after Top Line Data. 👇✌️🙏❤️‍🩹
1 replies
TraderDaKing Nov 13, 4:19 PM
$ELTP $PFE $MRNA $JNJ I know many Big Players will be on the call today. Will You??????? Management for Elite Pharmaceuticals, Inc. (OTCQB: ELTP) is hosting a live conference call today, Friday, November 13, 2026, at 11:30 AM EST. Conference Call Details • Purpose: To provide a corporate update and discuss the company's financial and operating results for the second quarter of fiscal year 2027. • Time: Today, November 13, 2026, at 11:30 AM EST • Investor Relations: You can find updates, replays, and filings through the Elite Pharmaceuticals Investor Relations Portal.
0 replies
SellasgpsCurativeBAT11 Nov 13, 4:12 PM
$SLS $JNJ $PFE $BMY $ABBV Lot of Biotechnology deals close before EOY for tax reasons. Do keep in mind Sellas has over $600 Million in NOL’s for the buyer! ✌️🙏❤️‍🩹
0 replies
Olg59 Nov 13, 4:12 PM
$PFE Re-entered under 28.70
0 replies
PFElinepfrenzy1990 Nov 13, 4:12 PM 1 replies
MarketToday Nov 13, 3:55 PM
$PFE manipulation
0 replies